Similarly, in HCC, FTO removes m6A modification from GLUT1 mRNA, counteracting YTHDF2-mediated degradation, increasing mRNA stability and expression, and ultimately enhancing glycolysis and lactate production [87]. The gene discussed is SLC2A1; the disease is hepatocellular carcinoma.